Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Features
Law firms are waiting to see how new trends like working remotely play out for office space post-pandemic, but that wait-and-see approach has created a tenant's market with opportunities for proactive firms in the short term.
Features
Many attorneys don't actually know how to scale business and require guidance in order to develop and exercise that muscle. This is precisely why law firms should invest in their associates' business development efforts from the start.
Features
A once-in-a-lifetime pandemic caused once-in-a-lifetime expense reductions that could forever alter the business of law. After those cost savings fueled double-digit profit growth for many firms in 2020, don't be surprised if Big Law leaders try to make some of those gains stick.
Columns & Departments
Eleventh Circuit Flirts With Nominative Fair Use Test in Alan Parsons Project Trademark Case
Features
Federal Circuit Wasn't Chicken to Grant Equitable Intervening Right in Poultry Processing Equipment Case A dispute between the two titans in the poultry processing equipment market led the U.S. Court of Appeals for the Federal Circuit to construe the term "protection of investments" in 35 U.S.C. §252.
Features
Chapter 11 work can be episodic and uneven, and while litigation skills are essential, it is also quite specialized. So, given these qualities, how does a bankruptcy litigator go about moving from one law firm to another, and what are the pitfalls?
Features
Data breaches, while frequent in number and severity, remain big news events today. Even more newsworthy is when a corporate in-house attorney is criminally prosecuted in connection with his role in responding to a data breach event.
Features
Just as the pandemic has challenged every aspect of our lives, the shift to a remote work environment has significantly impacted e-discovery and the ethical obligations of attorneys in this ever-evolving technological and legal landscape.
Columns & Departments
On March 12, the Federal Circuit granted Janssen Pharmaceutica's motion to dismiss Mylan Laboratories' appeal and denied Mylan's request for mandamus relief, holding that it lacked jurisdiction to hear Mylan's appeal.
